| General population (ages 50–89) | Overall estimated prevalence of **0.56%** (95% CI: 0.25–0.86%) based on population MRI screening |
| Ages 50–69 | Prevalence of 0.21% (95% CI: 0–0.45%) |
| Ages >69 | Prevalence rises to 1.43% (95% CI: 0.53–2.34%)[@perivascular] |
| Cortical SS in specific populations | Approximately 6–40% of patients with cerebral amyloid angiopathy, ~5% of Alzheimer's disease patients, ~2.5% of other dementias, and ~2% of those with mild cognitive impairment |
| Databases | OMIMOrphanetClinicalTrialsPubMed |